assortment of adverse skin effects are associated with the use of epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and erlotinib. Although papulopustular rash may be the most commonly observed side effect of these targeted agents, non
Search Results
Targeted Agents: Management of Dermatologic Toxicities
Barbara Burtness
Clinical Treatment Decisions for Advanced Renal Cell Cancer
Toni K. Choueiri
For the treatment of advanced renal cell cancer (RCC), 7 targeted agents have been approved in less than 8 years, which has greatly extended progression-free survival (PFS; Table 1 ). As even more targeted agents emerge from the pipeline, the
Clinical Discussion and Review of the Management of Brain Metastases
Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh
, which must be further investigated. 80 Table 2 Prospective Trials of Targeted Agents in Brain Metastases The role of bevacizumab is also being explored. In a small case series of 4 patients with central nervous system metastases from
Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma
Leo I. Gordon
response rate was 87%, which Dr. Gordon called “fairly exciting data in a small number of patients, most of whom were naïve to brentuximab vedotin.” However, he noted, there were few CRs (17%). Table 1. Targeted Agents in Hodgkin Lymphoma
Treatment of Metastatic Pancreatic Cancer
Andrew H. Ko and Margaret A. Tempero
Pancreatic adenocarcinoma represents the fourth-leading cause of cancer-related mortality in the United States. The vast majority of patients are diagnosed at advanced stages of the disease when surgery is no longer an option. For these patients, systemic therapy remains the mainstay of care. Although single-agent gemcitabine has remained the standard of care since its approval in 1997, improvements in patient outcomes may potentially be realized by (1) applying pharmacokinetic principles to optimize drug delivery, such as the administration of gemcitabine at a “fixed-dose rate” infusion; (2) combining gemcitabine with other cytotoxic agents for which evidence of synergy exists, such as platinum compounds; and (3) integrating novel targeted agents such as bevacizumab, erlotinib, and cetuximab into treatment paradigms, based on an increasing understanding of the molecular pathways that govern pancreatic tumor growth and maintenance. This article provides the evidence to support each of these approaches and highlights future directions in the management of metastatic pancreatic cancer.
Combining Systemic Therapy With Radiation: Head and Neck Cancer Treatments in an Era of Targeted Agents and Immunotherapy
Harish N. Vasudevan and Sue S. Yom
of cisplatin, details of RT, and patient and tumor characteristics, will be important to guide more precise treatment regimens for individual patients. Alternatives to Cisplatin: Second-Line Cytotoxic Therapies, Targeted Agents, and Immunotherapy
Emerging Multimodality Approaches to Treat Localized Esophageal Cancer
Ronan J. Kelly
, eliminate micrometastatic disease, and increase pCR, which is a surrogate of long-term survival. 37 Table 2. Ongoing Trials Investigating HER2-Targeted Agents or Checkpoint Inhibitors CheckMate 577 ( ClinicalTrials.gov identifier: NCT02743494 ) is studying
Targeted Strategies in the Treatment of Metastatic Colon Cancer
Diane Reidy and Leonard Saltz
malignancies [abstract] . J Clin Oncol 2003 ; 22 ( Suppl 1 ): Abstract 817 . 25. Saltz LB Perez-Soler R . Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005 ; 23 : 5235 – 5246 . 26
Practice-Changing Interventions in the Systemic Management of Breast Cancer
Presented by: William J. Gradishar
Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from
Emerging Therapies in the Treatment of Bladder Cancer
Presented by: Arlene O. Siefker-Radtke
Therapy Enfortumab Vedotin “Following this frontline standard, we now have multiple targeted agents,” commented Dr. Siefker-Radtke. She began by discussing enfortumab vedotin, which was the first antibody–drug conjugate to be approved for the
